Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously tr ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Date/Time: Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com.

Date/Time: Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archive replays ...

Coincidentally, UFO expert, Carl Nally of UFO and Paranormal Research Ireland (UPRI), claimed this week that the spate of recent mysterious drone sightings could be a precursor to an alien invasion.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mersana Therapeutics has a one year low of $0.49 and a one year high of $6.28. The company has a 50 day moving average of $1.08 and a 200-day moving average of $1.62.